FDA And NIH Jointly Release PATH Seventh Wave Data To Support Health Research Related To Tobacco Products
Leave a message
FDA and NIH jointly release PATH seventh wave data to support health research related to tobacco products
The US FDA and NIH have released the seventh wave of biomarker data files for the Tobacco and Health Population Assessment Study, which includes for the first time biomarker data collected between January 2022 and April 2023.
According to a joint announcement by the US Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIH), the seventh wave of the Tobacco and Health Population Assessment (PATH) biomarker data file (BRUF) has been released. This is the first release of the seventh wave of biomarker data collected between January 2022 and April 2023.
According to the official website of the FDA, the PATH study is a large-scale, long-term study on tobacco use and health in the United States. This study was conducted in collaboration between the FDA Tobacco Products Center and the NIH National Institute on Drug Abuse. It was initiated in 2011 and the first round of data collection began in 2013.
The main purpose of this study is to help scientists understand the ways and reasons why people start smoking, quit smoking, and smoke again after quitting, as well as the impact of different tobacco products on health (such as cardiovascular and respiratory health), by tracking the research subjects for a long time. In addition, the research findings may provide reference for the FDA to develop actions related to tobacco products, thereby helping to achieve the goals of the Family Smoking Prevention and Tobacco Control Act.
The FDA official website shows that researchers can apply to access these restricted biomarker data files (BRUF). In addition, the first wave of data files has also been updated, with new samples including adults who have experimentally or long-term used any tobacco products. The main link files for restricted and publicly available use have also been updated to reflect the new files and the currently available samples in the biological sample acquisition plan.
